Podcast: Adams & Adams discusses the challenges of registration in Africa

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

Podcast: Adams & Adams discusses the challenges of registration in Africa

Sponsored by

Adams & Adams logo.jpg
L to R: Jenny Pienaar and Kareema Shaik of Adams & Adams

Jenny Pienaar and Kareema Shaik of Adams & Adams consider pharmaceutical registration in the larger African markets, dealing with the challenges of registration and the subsequent enforcement of rights

In the second episode of the three-part podcast series by Adams & Adams on the IP enforcement of pharma in Africa, partners Jenny Pienaar and Kareema Shaik talk to Managing IP about pharmaceutical registration in the larger African markets.

The international registration system counts many African states as members – but its use is patchy. Although the Madrid System is effective globally, there are challenges to its efficiency in Africa. This is mainly due to varying local IP laws and registry systems across the continent. The experts explain how these obstacles can be overcome and how legal avenues are available to effectively address challenges.

The experts discuss the realities of the enforcement environment amid the COVID-19 pandemic and typical roadblocks faced by innovators because of problems attached to registration, while providing country-based examples to assist business leaders and consumers who work in the African IP field.

About Adams & Adams

Adams & Adams is an internationally recognised and leading African law firm that specialises in providing intellectual property, corporate and commercial services.

The firm is firmly rooted in Africa – with a tenacious belief in the economic growth potential and spirit of the continent. The head office in Pretoria, the capital of South Africa, provides the perfect gateway through which our partners, supported by some 700 professionals and staff, render a broad range of legal services to clients in Africa and the rest of the world. 

Through its associate offices and long established networks, the firm serves a global client base throughout the African continent - in matters of intellectual property, commercial law, property and litigation.


Related content

Podcast: Adams & Adams discuss trends in anti-counterfeiting across Africa

Podcast: Adams & Adams discuss trends in patent litigation across South Africa

You can find all Managing IP podcasts here.


more from across site and SHARED ros bottom lb

More from across our site

Junior lawyers aren’t unwilling to work hard, as some seniors believe; rather, they are rejecting traditional career advancement models that have limited payoff
Rebekah Gay discusses overcoming self-doubt, supporting the next generation of women lawyers, and how changing client demands are reshaping IP practice
New filing data suggests Germany's grip on UPC litigation remains strong, while Bardehle Pagenberg, Arnold Ruess, Hogan Lovells and Carpmaels notch up notable cases
In 27 years, KASS has expanded to seven countries in southeast Asia and is now eyeing further growth opportunities. Its CEO shares her perspective
Mine Güner discusses bridging law and business, taking the initiative, and why Taylor Swift helped put copyright on the map
Cindy Goh discusses why she launched Cheang & Ariff's IP department, the improving litigation environment in Malaysia and what to consider when using AI
Increased focus on adding patent litigation depth to the firm’s Dallas office was behind the boutique’s most recent hires
IPH's Canadian acquisitions are paying off on paper, but a couple of strong years may not be enough to show that the group's strategy has truly won over the market
Examiner statistics could help patent prosecution practitioners tailor strategies, turning an area of high variability into a potential competitive advantage
The England and Wales High Court’s ruling in Accord v Novartis may not rewrite the law on plausibility, but it does signal a pragmatic approach that could provide greater certainty for life sciences innovators
Gift this article